GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diaceutics PLC (LSE:DXRX) » Definitions » Return-on-Tangible-Equity

Diaceutics (LSE:DXRX) Return-on-Tangible-Equity : -20.78% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Diaceutics Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Diaceutics's annualized net income for the quarter that ended in Jun. 2024 was £-5.17 Mil. Diaceutics's average shareholder tangible equity for the quarter that ended in Jun. 2024 was £24.87 Mil. Therefore, Diaceutics's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was -20.78%.

The historical rank and industry rank for Diaceutics's Return-on-Tangible-Equity or its related term are showing as below:

LSE:DXRX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -11.42   Med: 3.55   Max: 75.15
Current: -11.42

During the past 8 years, Diaceutics's highest Return-on-Tangible-Equity was 75.15%. The lowest was -11.42%. And the median was 3.55%.

LSE:DXRX's Return-on-Tangible-Equity is ranked worse than
78.97% of 561 companies
in the Healthcare Providers & Services industry
Industry Median: 10.76 vs LSE:DXRX: -11.42

Diaceutics Return-on-Tangible-Equity Historical Data

The historical data trend for Diaceutics's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diaceutics Return-on-Tangible-Equity Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial 4.47 1.11 1.91 2.63 -6.61

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.62 11.03 -11.36 -2.07 -20.78

Competitive Comparison of Diaceutics's Return-on-Tangible-Equity

For the Health Information Services subindustry, Diaceutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diaceutics's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Diaceutics's Return-on-Tangible-Equity falls into.



Diaceutics Return-on-Tangible-Equity Calculation

Diaceutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-1.746/( (27.292+25.524 )/ 2 )
=-1.746/26.408
=-6.61 %

Diaceutics's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=-5.168/( (25.524+24.218)/ 2 )
=-5.168/24.871
=-20.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Diaceutics  (LSE:DXRX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Diaceutics Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Diaceutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Diaceutics Business Description

Traded in Other Exchanges
Address
Kings Hall Health and Wellbeing Park, Dataworks, First Floor, Building Two, Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.

Diaceutics Headlines

No Headlines